Armata Pharmaceuticals
4503 Glencoe Avenue
Marina del Rey
California
90292
United States
Tel: 310-665-2928
Fax: 310-665-2963
Website: http://www.armatapharma.com/
93 articles about Armata Pharmaceuticals
-
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
3/4/2024
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company") today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder.
-
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit
2/21/2024
Armata Pharmaceuticals, Inc. today announced that Mina Pastagia , M.D., Chief Medical Officer, will deliver a presentation at the 6th Annual Bacteriophage Therapy Summit, which is being held February 27-29 in Boston.
-
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
11/14/2023
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2023, and provided a corporate update.
-
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference
10/30/2023
Armata Pharmaceuticals, Inc. today announced that topline data from the Company's Phase 1b /2a SWARM- P.a. clinical trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in people with cystic fibrosis (CF) will be mentioned during the North American Cystic Fibrosis Conference (NACFC) Plenary II session.
-
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023
10/19/2023
Armata Pharmaceuticals, Inc. today announced that its Chief Medical Officer, Mina Pastagia , M.D., MS, will deliver a presentation at Phage Futures: Global Digital Summit 2023, which is being held virtually on October 25th.
-
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus
9/26/2023
Armata Pharmaceuticals, Inc. today announced that the first patient has been dosed in the Phase 2a portion of the Company's diSArm study of AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia. Initiation of the Phase 2a portion of the study follows Data Review Committee (DRC) review of positive safety and tolerability data from the Phase 1b portion.
-
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
9/21/2023
Armata Pharmaceuticals, Inc. today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a panel discussion at the Cantor Global Healthcare Conference, which is being held in New York from September 26-28, 2023.
-
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update
8/14/2023
Armata Pharmaceuticals, Inc. today announced financial results for its second quarter ended June 30, 2023, and provided a corporate update.
-
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
7/11/2023
Armata Pharmaceuticals, Inc. today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva").
-
Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy
5/31/2023
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced an oral presentation on the company's recently completed Phase 1b/2a SWARM-P.a. clinical trial at the 6th World Conference on Targeting Phage Therapy.
-
Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update
5/11/2023
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company") today announced financial results for its first quarter ended March 31, 2023, and provided a corporate update.
-
Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis
3/6/2023
Armata Pharmaceuticals, Inc. today announced positive topline results from the completed Phase 1b/2a SWARM-P.a. trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients.
-
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC
1/10/2023
Armata Pharmaceuticals, Inc. today announced that it has closed a secured convertible credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder.
-
Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
12/22/2022
Armata Pharmaceuticals, Inc. today announced that the last subject has completed the company's Phase 1b /2a 'SWARM- P.a.' clinical trial of its lead candidate, AP-PA02, in cystic fibrosis (CF) subjects with chronic pulmonary Pseudomonas aeruginosa infection.
-
Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
11/28/2022
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the company will participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage, which is being held virtually on November 30, 2022.
-
Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update
11/9/2022
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter 2022 and provided a corporate update.
-
Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update
8/11/2022
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter 2022 and provided a corporate update.
-
Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections
8/1/2022
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), today announced that the U.S. Food and Drug Administration (FDA) has cleared Armata's Investigational New Drug (IND) application for AP-SA02 in prosthetic joint infection (PJI).
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
Burlingame, CA-based Innoviva is buying all of Waltham, MA-based Entasis Therapeutics' available shares at $2.20 per share. Currently, Innoviva owns about 60% of Entasis’ outstanding shares.